Related Experiment Video

Updated: Apr 20, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K

Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases

Tulasi Gummadi1, Ben Y Zhang, Sara Valpione

  • 1aMasonic Cancer Center, University of Minnesota, Minneapolis bDepartment of Medical Oncology, Mayo Clinic cMidwest Melanoma Partnership, Rochester, Minnesota dDivision of Hematology/Oncology, University of Illinois Cancer Center, Chicago, Illinois, USA eIstituto Oncologico, Veneto, Padova, Italy.

Melanoma Research
|November 27, 2014
PubMed

Insights

BRAF mutations do not affect brain metastasis incidence in melanoma. However, vemurafenib treatment in BRAF-mutated melanoma patients was associated with a lower incidence of brain metastases, suggesting a potential preventative effect.

Area of Science:

  • Oncology
  • Dermatology
  • Medical Research

Background:

  • The role of BRAF mutations in metastatic melanoma's brain metastasis development and prognosis is unclear.
  • The effect of BRAF inhibitors on brain metastasis incidence requires further definition.

Purpose of the Study:

  • To investigate the impact of BRAF mutations on brain metastasis incidence in metastatic melanoma.
  • To evaluate the effect of the BRAF inhibitor vemurafenib on brain metastasis incidence.

Main Methods:

  • Retrospective analysis of 436 metastatic melanoma patients across three institutions.
  • Examined the correlation between BRAF mutation status, vemurafenib treatment, and brain metastasis development.

Main Results:

  • No significant difference in brain metastasis incidence was found between BRAF-mutated and non-mutated melanoma patients.
  • Patients with BRAF-mutated tumors receiving vemurafenib prior to brain metastasis diagnosis showed a reduced incidence of brain metastases (IRR=0.51, P=0.009).
  • Vemurafenib improved extracranial disease control but did not significantly impact intracranial disease progression or survival.

Conclusions:

  • BRAF mutation status alone does not alter the risk of developing brain metastases in melanoma.
  • Vemurafenib may reduce the incidence of brain metastases in BRAF-mutated melanoma patients, despite limited brain penetration.
  • Further research is warranted to confirm vemurafenib's role in preventing brain metastases in this population.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.5K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

4.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.2K